Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Depreciation and Depletion (2022 - 2023)

Phathom Pharmaceuticals (PHAT) has disclosed Depreciation and Depletion for 2 consecutive years, with $100000.0 as the latest value for Q3 2023.

  • Quarterly Depreciation and Depletion fell 50.0% to $100000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $400000.0 through Sep 2023, changed N/A year-over-year, with the annual reading at $600000.0 for FY2022, 20.0% up from the prior year.
  • Depreciation and Depletion for Q3 2023 was $100000.0 at Phathom Pharmaceuticals, roughly flat from $100000.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $200000.0 in Q3 2022, with the low at $100000.0 in Q1 2022.